CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.560
+0.090 (3.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
CytoMed Therapeutics Cash Flow Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -3.06 | -4.13 | -3.13 | -2.05 | -1.94 | -0.85 |
| Depreciation & Amortization | 0.34 | 0.38 | 0.39 | 0.33 | 0.29 | 0.18 |
| Other Amortization | 0 | 0 | 0 | 0 | - | - |
| Loss (Gain) From Sale of Assets | - | - | -0 | - | - | - |
| Asset Writedown & Restructuring Costs | - | - | 0 | - | - | - |
| Loss (Gain) on Equity Investments | -0 | 0.03 | 0.03 | 0.21 | - | - |
| Other Operating Activities | -0.03 | 0.18 | 1.2 | 0.17 | 0.68 | 0.03 |
| Change in Accounts Receivable | 0.15 | -0.01 | -0.15 | -0.43 | -0.16 | 0.01 |
| Change in Inventory | - | - | - | - | - | -0.05 |
| Change in Accounts Payable | 0.05 | 0.11 | 0.26 | 0.06 | 0.28 | 0.05 |
| Operating Cash Flow | -2.56 | -3.43 | -1.4 | -1.71 | -0.85 | -0.63 |
| Capital Expenditures | -0.95 | -0.06 | -0.47 | -0.58 | -0.24 | -1.17 |
| Sale of Property, Plant & Equipment | - | - | 0 | - | - | - |
| Sale (Purchase) of Intangibles | - | - | - | - | -0.02 | - |
| Investment in Securities | 2.19 | -2.77 | - | -0.24 | -0.25 | - |
| Investing Cash Flow | 0.74 | -2.83 | -0.47 | -0.82 | -0.51 | -1.17 |
| Short-Term Debt Issued | - | - | 0.3 | 0.35 | 1.5 | 0.25 |
| Total Debt Issued | - | - | 0.3 | 0.35 | 1.5 | 0.25 |
| Short-Term Debt Repaid | - | -0.3 | -0.35 | - | - | - |
| Long-Term Debt Repaid | - | -0.04 | -0.08 | -0.06 | -0.01 | -0.03 |
| Total Debt Repaid | -0.01 | -0.34 | -0.43 | -0.06 | -0.01 | -0.03 |
| Net Debt Issued (Repaid) | -0.01 | -0.34 | -0.13 | 0.29 | 1.49 | 0.22 |
| Issuance of Common Stock | - | 11.31 | 1.22 | 4 | 0.5 | 1 |
| Other Financing Activities | -0.02 | -0.05 | -0.13 | -0.12 | -0.11 | -0.03 |
| Financing Cash Flow | -0.03 | 10.92 | 0.97 | 4.17 | 1.88 | 1.19 |
| Foreign Exchange Rate Adjustments | 0.07 | -0.01 | -0.03 | -0.01 | -0.01 | -0 |
| Net Cash Flow | -1.77 | 4.64 | -0.93 | 1.63 | 0.51 | -0.62 |
| Free Cash Flow | -3.51 | -3.49 | -1.87 | -2.3 | -1.09 | -1.81 |
| Free Cash Flow Margin | -783.19% | -687.59% | -514.47% | -2016.27% | -1839.93% | - |
| Free Cash Flow Per Share | -0.30 | -0.33 | -0.24 | -0.33 | -0.19 | -0.33 |
| Cash Interest Paid | 0.02 | 0.05 | 0.13 | 0.12 | 0.11 | 0.03 |
| Cash Income Tax Paid | 0 | 0 | - | - | - | - |
| Levered Free Cash Flow | -2.59 | -2.04 | -1.29 | -1.75 | -1.28 | - |
| Unlevered Free Cash Flow | -2.58 | -2.01 | -1.21 | -1.68 | -1.22 | - |
| Change in Net Working Capital | -0.19 | -0.07 | -0.03 | 0.34 | 0.42 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.